Observational studyClinical cardiology2017
Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease.
Observational study in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Real-world analysis of characteristics and guideline adherence of antiplatelet drugs prescriptions among patients with coronary artery disease and its comorbidities: a cross-sectional study.BMC cardiovascular disorders · 2025Article
- Comparative Ten-Year Outcomes in Chronic and Acute Coronary Syndrome Patients Undergoing Invasive Diagnostics-Insights from the KORONEF Registry.Biomedicines · 2024Article
- New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry.European heart journal · 2024Observational
- A comparison of the management and five-year outcomes of patients treated for chronic coronary syndrome between 2006-2007 and 2015-2016 - insights from the PRESAGE registry.Cardiology journal · 2024Observational
- Two-Year Follow-Up of Chronic Ischemic Heart Disease Patients in a Specialized Center in Brazil.Arquivos brasileiros de cardiologia · 2023Article
- Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention.Frontiers in cardiovascular medicine · 2023Review
- Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study.Cardiology and therapy · 2022Article
- Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data.European heart journal. Digital health · 2022Article
- International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study.Circulation · 2021Article
- Profiles of Hospitalized Patients with Angiographic Coronary Heart Disease in Taiwan during 2014-2016: Report of a Tertiary Hospital.Acta Cardiologica Sinica · 2021Article
- Simple risk models to predict cardiovascular death in patients with stable coronary artery disease.European heart journal. Quality of care & clinical outcomes · 2021Article
- Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry.Clinical cardiology · 2021Article
- Management of Patients with Coronary Artery Disease in Lithuania: a Comparison with Other Central Eastern European Countries Based on Data From the International CLARIFY Registry.Advances in therapy · 2020Observational
- Direct-acting Anticoagulants in Chronic Coronary Syndromes.European cardiology · 2020Review
- Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.European heart journal · 2020Observational
- Secondary prevention and outcomes in outpatients with coronary artery disease, atrial fibrillation or heart failure: a focus on disease overlap.Open heart · 2020Article
- Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry.Journal of clinical medicine · 2019Article
- Effectiveness and Impact on Adherence of a New Fixed-Dose Combination of Ivabradine and Metoprolol in a Wide Range of Stable Angina Patients in Real-Life Practice.Cardiology and therapy · 2019Article
- β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.European heart journal · 2019Article
- Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry.European heart journal · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite major advances in prevention and treatment, coronary artery disease (CAD) remains the leading cause of death worldwide. Whereas many sources of data are available on the epidemiology of acute coronary syndromes, fewer datasets reflect the contemporary management and outcomes of stable CAD patients. HYPOTHESIS: A worldwide contemporary registry would improve our knowledge about stable CAD. The main objectives are to describe the demographics, clinical profile, contemporary management and outcomes of outpatients with stable CAD; to identify gaps between evidence and treatment; and to investigate long-term prognostic determinants.
methodsCLARIFY (ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) is an ongoing international observational longitudinal registry. Stable CAD patients from 45 countries in Europe, Asia, America, Middle East, Australia and Africa were enrolled between November 2009 and June 2010. The inclusion criteria were previous myocardial infarction, evidence of coronary stenosis >50%, proven symptomatic myocardial ischemia or prior revascularization procedure. The main exclusion criteria were serious non-cardiovascular disease, conditions interfering with life expectancy or severe other cardiovascular disease (including advanced heart failure). Follow-up visits were planned annually for up to 5 years, interspersed with 6-month telephone calls.
resultsOf the 32,703 patients enrolled, most (77.6%) were male, age (mean ± SD) was 64.2 ± 10.5 years, and 71.0% were receiving treatment for hypertension; mean ± SD resting heart rate was 68.2 ± 10.6 bpm. Patients were enrolled based on a history of myocardial infarction >3 months earlier (57.7%), having at least one stenosis >50% on coronary angiography (61.1%), proven symptomatic myocardial ischemia on non-invasive testing (23.1%), or history of percutaneous coronary intervention or coronary artery bypass graft (69.8%). Baseline characteristics were similar across the four subgroups identified by the four inclusion criteria.
conclusionCLARIFY will provide a useful resource for understanding the current epidemiology of stable CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.